ArticleCase orthopaedic journal
THE COP9 SIGNALOSOME, A NOVEL, ESSENTIAL REGULATOR OF SKELETAL DEVELOPMENT AND TUMORIGENESIS.
Article in Case orthopaedic journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Signaling pathways regulating cartilage growth plate formation and activity.Seminars in cell & developmental biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
In recent years, the evolutionarily conserved complex named COP9 signalosome has emerged as an essential and versatile regulator of biological and pathological responses across species. Various components of COP9 signalosome, including CSN5 (also named JAB1), play critical roles in a wide array of developmental process. Using genetically engineered mouse models, our laboratory has recently identified CSN5/JAB1 as an essential regulator of skeletal development, in part through negatively regulating BMP signaling. BMP signaling is important for fracture healing and bone regeneration. BMPs have been used for treating acute fractures and for improving the success of spinal fusions. Therefore, harnessing the CSN5/JAB1-mediated inhibition of BMP signaling might be a novel strategy to improve the efficacy of BMP treatment and to reduce medical costs in the future. Furthermore, the up-regulation of COP9 signalosome has been associated with various cancers, including osteosarcoma. Thus, the COP9 signalosome can also be a valid target for treating osteosarcoma and other tumors.
Identifiers
26807424PMC4722531W2411446521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.